Fresenius Medical Care AG banner

Intrinsic Value

The intrinsic value of Fresenius Medical Care AG (FME) under the Base Case is 42.27 EUR per share. Compared with the current market price of 39.59 EUR, the stock appears Undervalued by 6% .

The intrinsic value is calculated using the DCF method. The model assumes Fresenius Medical Care's net margin rises to 6.5% by 2031, near its six-year high and above last year's 5%. If its margin stayed at its five-year average of 3.9%, the estimate would be about €38. Margins affect only the forecast years; the value of the years after 2031 uses a revenue multiple.

Do our valuations actually work? See backtest results .

FME Intrinsic Value
€42.27
Undervaluation 6%
Intrinsic Value
Price €39.59
Alert me when FME is below its intrinsic value
Today €33.82 · 14.6% below the current price

FME is valued in line with its history. A discount of this size has been typical over the past 5 years.

Alternatives to FME

Fundamental Analysis

What Fresenius Medical Care Does

Health Care

Fresenius Medical Care AG is one of the world’s main kidney care companies. It treats patients with chronic kidney failure by running dialysis clinics and by providing dialysis treatments in hospitals and care centers. It also sells the equipment, filters, and related supplies needed to deliver dialysis, which makes it both a care provider and a medical products supplier.

Headquarters
Germany DE
Employees
123 106
IPO date
Oct 2, 1996
Read the full company overview
View Company Overview

Fresenius Medical Care has no economic moat

No Moat Narrow Wide

In much of the U.S., government reimbursement and competition based on care quality, access, and physician referrals leave little evidence that the Fresenius name lets the company charge more. Patients and doctors can choose other dialysis providers, and Fresenius’s scale does not make its services more valuable simply because more people use them.

Read the full moat analysis
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Latest Earnings Call

Q3 2026 · November 3, 2026

Fresenius Medical Care kept its 2026 revenue outlook broadly flat but narrowed its operating-income outlook, citing a more pressured second half and higher inflation headwinds.

Open the earnings call
Stock, next trading day
+0.5%
View Earnings Call

Past 12 months

Continue FME Research

Decided on Fresenius Medical Care? Get an email when FME reaches the price you’d buy at. Free with an account.

Other Fresenius Medical Care listings

What is the Intrinsic Value of one FME stock?

The intrinsic value for Fresenius Medical Care AG (FME) under the Base Case is 42.27 EUR.

Is FME stock undervalued or overvalued?

Compared with the current market price of 39.59 EUR, the stock appears Undervalued by 6% .

How reliable are our estimates? See how past valuations played out
Back to Top